Catalent Inc (NASDAQ:CTLT) Shares Bought by Bank of Montreal Can
Bank of Montreal Can raised its stake in Catalent Inc (NASDAQ:CTLT) by 7,372.1% during the second quarter, Holdings Channel reports. The institutional investor owned 82,716 shares of the company’s stock after buying an additional 81,609 shares during the period. Bank of Montreal Can’s holdings in Catalent were worth $2,903,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. acquired a new position in Catalent during the fourth quarter valued at $426,000. Teachers Advisors LLC boosted its position in Catalent by 3.0% in the fourth quarter. Teachers Advisors LLC now owns 164,748 shares of the company’s stock valued at $4,442,000 after buying an additional 4,823 shares in the last quarter. Capstone Asset Management Co. boosted its position in Catalent by 3.4% in the first quarter. Capstone Asset Management Co. now owns 9,900 shares of the company’s stock valued at $280,000 after buying an additional 330 shares in the last quarter. Parametrica Management Ltd acquired a new position in Catalent during the first quarter valued at $308,000. Finally, Fox Run Management L.L.C. acquired a new position in Catalent during the first quarter valued at $346,000.
Catalent Inc (NASDAQ:CTLT) traded down 0.55% during trading on Wednesday, reaching $34.44. The company’s stock had a trading volume of 92,554 shares. Catalent Inc has a 52-week low of $21.83 and a 52-week high of $38.73. The stock has a market cap of $4.30 billion and a P/E ratio of 40.57. The firm’s 50-day moving average is $35.81 and its 200-day moving average is $31.53.
Several equities analysts recently weighed in on CTLT shares. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $32.00 price objective for the company in a research report on Tuesday, April 11th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, April 19th. William Blair raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Friday, May 5th. Bank of America Corporation reissued a “buy” rating and set a $37.00 price objective (up previously from $32.00) on shares of Catalent in a research report on Wednesday, May 17th. Finally, BidaskClub cut Catalent from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $32.00.
In other Catalent news, SVP Christine Dolan sold 745 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $34.85, for a total transaction of $25,963.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.